Register Login
Register to leave comments
  • News bot Jan. 8, 2026, 1:14 p.m.

    📋 Spruce Biosciences, Inc. (SPRB) - Regulatory Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 08:05:27

    Event Type: Regulatory Update

    Event Details:

    Spruce Biosciences Inc (SPRB) Announces Regulatory Update Spruce Biosciences Inc (SPRB) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: • Applications: BLA (Biologics License Application) • Regulatory Agencies: FDA (U.S. Food and Drug Administration) • Status: Approved, Rejected, Extended Review Clinical Development:

    🔬 Clinical Development Pipeline (Spruce Biosciences, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Tildacerfont DRUG Phase PHASE2 Congenital Adrenal Hyperplasia ClinicalTrials.gov
    SPR001 DRUG Phase PHASE2 Congenital Adrenal Hyperplasia ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Polycystic Ovary Syndrome ClinicalTrials.gov
    Tildacerfont/Placebo DRUG Phase PHASE2 Congenital Adrenal Hyperplasia ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Spruce Biosciences Inc
    • CIK: 0001683553
    • Ticker Symbol: SPRB
    • Period End Date: 2026-01-07
    • Document Type: 8-K

Search

News categories